CBI Research

Comparative Biosciences (CBI) is a specialized preclinical contract research organization (CRO) providing discovery and GLP-compliant toxicology services to the life sciences industry. The company offers expertise in a variety of therapeutic areas, including ophthalmology, dermatology, oncology, and wound healing, with a focus on high-quality histopathology and complex surgical models. CBI's services encompass pharmacokinetics, efficacy studies, and safety assessment for small molecules, biologics, and medical devices. In 2021, CBI was acquired by Genesis Drug Discovery & Development (GD3), a member of the Genesis Biotechnology Group, integrating its capabilities into a broader drug discovery and development portfolio.